| (USD) | Dec 2023 | Q/Q |
|---|---|---|
| Revenue | 14.2MM | +4% |
| Gross Profit | 12.4MM | +8% |
| Cost Of Revenue | 1.8MM | -15% |
| Operating Income | -12.3MM | +32% |
| Operating Expenses | 24.7MM | +17% |
| Net Income | -7.1MM | -19% |
| R&D | 6.8MM | +54% |
| G&A | 7.8MM | +27% |
| Marketing | 10.2MM | -3% |
| Amortization | 9K | - |
| Interest Expense | 1.1MM | - |
Short Volume Ratio = Short Volume / All Volume. Source of Short Volume data comes from
FinraMoving Average Convergence/Divergence oscillator (MACD) is one of the simplest and most effective momentum indicators available.
Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. RSI oscillates between zero and 100. According to Wilder, RSI is considered overbought when above 70 and oversold when below 30.
VALENCIA, Calif., April 15, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that it will report its first quarter 2024 financial results after the close of the U.S. financial markets on Monday, May 13, 2024. AVITA Medical will host a conference call and webcast that day at 1:30 p.m. Pacific Time (Tuesday, May 14, 2024, at 6:30 a
VALENCIA, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced an update to its expected commercial revenue for the first quarter of 2024 and reaffirmed expectations for full-year 2024 revenue at the lower end of the previously provided guidance of US$78.5 million to US$84.5 million. For the quarter ended March 31,
While not a mind-blowing move, it is good to see that the AVITA Medical, Inc. ( NASDAQ:RCEL ) share price has gained...
Viewing insider transactions for AVITA Medical, Inc.'s ( NASDAQ:RCEL ) over the last year, we see that insiders were...
VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced it has submitted its response to the U.S. Food and Drug Administration (FDA) for additional information requested in connection to its premarket approval (PMA) supplement for RECELL GO™. This submission resumes the substantive interactive review process u
VALENCIA, Calif., Feb. 29, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, today announced that David O’Toole, Chief Financial Officer, will present at TD Cowen’s 44th Annual Health Care Conference on Tuesday, March 5, 2024, at 9:50 a.m. Eastern Time. A live audio webcast of the presentation will be available under the Events & Presentations se
AVITA Medical, Inc. ( NASDAQ:RCEL ) shareholders are probably feeling a little disappointed, since its shares fell 2.2...
AVITA Medical, Inc. (NASDAQ:RCEL) Q4 2023 Earnings Call Transcript February 22, 2024 AVITA Medical, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day and thank you for standing by. Welcome to the AVITA Medical Fourth Quarter 2023 Earnings […]
VALENCIA, Calif., Feb. 23, 2024 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a commercial-stage regenerative medicine company focused on first-in-class devices for wound care management and skin restoration, invites shareholders and prospective investors to attend its investor webinar briefing and presentation by Jim Corbett, Chief Executive Officer, and David O’Toole, Chief Financial Officer, on February 27, 2024, at 2:00 p.m. (PST) / February 28, 2024, at 9:00 a.m. (AEDT).
Company Forecasts Continued Expansion and Profitability by Q3 2025